| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0995 | Bin-01-07-07 | Novel USP28 inhibitor |
|
| DCC0996 | Bio-0554019 | Novel selective RORgamma inhibitor, selectively inhibiting Th17 differentiation and RORgamma signature gene expression |
|
| DCC0997 | Bipbipu | Novel heparanase inhibitor |
|
| DCC0998 | Biph(2,3',4,5',6)p5 | Potent inhibitor of SHIP-2 catalytic activity; Novel inositol polyphosphate surrogate modulating Ca responses in rat hepatocytes |
|
| DCC0999 | Biphalin | Potent peptide opioid receptor agonist, alleviating LPS-Induced activation in rat primary microglial cultures in opioid receptor-dependent and receptor-independent manners |
|
| DCC1000 | Bis-2-ai Adjuvant-2 | Novel adjuvant to repurpose azithromycin for use against Pseudomonas aeruginosa, exhibiting a 1024-fold reduction in the minimum inhibitory concentration of azithromycin in vitro and displays activity in a Galleria mellonella model of infection |
|
| DCC1001 | Bis-5-methyl-cyclosal-d4tmp | Novel anti-HIV active dimeric prodrug of 2‘,3‘-dideoxy-2‘,3‘-didehydrothymidine monophosphate (d4TMP) |
|
| DCC1002 | Bisaramil | Class I antiarrhythmic agent with chronotropic, inotropic, dromotropic and coronary vasodilator effects, potently blocking sodium channel |
|
| DCC1003 | Bis-cyclosal-d4tmp | Novel anti-HIV active dimeric prodrug of 2‘,3‘-dideoxy-2‘,3‘-didehydrothymidine monophosphate (d4TMP) |
|
| DCC1004 | Bisdionin F | Selective hAMCase Inhibitor |
|
| DCC1005 | Bisindole-pbd | Novel inhibitor of angiogenesis by regulating STAT3 and VEGF in breast cancer cells |
|
| DCC1006 | Bisleuconothine A | Novel and selective Wnt signaling inhibitor |
|
| DCC1007 | bis-n-norgliovictin | Novel inhibitor of LPS-induced inflammation in macrophages, improving survival in sepsis |
|
| DCC1008 | Bisoctrizole | UV stabilizer |
|
| DCC1009 | Bis-salicyl Fumarate | Potent activator of the Neh2-luc reporter |
|
| DCC1010 | Bisthianostat | Novel Orally Efficacious Pan-HDAC Inhibitor |
|
| DCC1011 | Bitc-sg | Inactivator of GSTP1>GST P1-1 through the covalent modification of two Cys47 residues per dimer and one Cys101 |
|
| DCC1012 | Bit-l15 | Novel potent antagonist of RORγt function, displaying an increased selectivity for RORγt over RORα and PPARγ compared to the purely orthosteric and allosteric non-PEG-linked parent compounds |
|
| DCC1013 | Bix-02188me | Potent and selective dual inhibitor of MEK5 and ERK5 |
|
| DCC1014 | Bjff078 | Potent inhibitor of recombinant human and mouse Transglutaminase enzyme activity, mainly TG2 and the close related enzyme TG1 |
|
| DCC1015 | Bjp-06-005-3 | Novel potent and selective covalent Pin1 inhibitor |
|
| DCC1016 | Bki-1708 | Novel Bumped-Kinase Inhibitor (BKI) for Cryptosporidiosis Therapy |
|
| DCC1017 | Bki-1770 | Novel Bumped-Kinase Inhibitor (BKI) for Cryptosporidiosis Therapy |
|
| DCC1018 | Bki-1812 | Novel potent and selective bumped kinase inhibitor (BKI) CpCDPK1 IC 50 0.0025 µM |
|
| DCC1019 | Bki-1814 | Novel potent and selective bumped kinase inhibitor (BKI) CpCDPK1 IC 50 0.005 µM |
|
| DCC1020 | Bkm1644 | Novel inhibitor of survivin transcription through a signal transducer and activator of transcription 3 (Stat3)-dependent mechanism, inhibiting tissue expression of survivin and inducing apoptosis in C4-2 skeletal tumor |
|
| DCC1021 | Bkm1740 | Novel effective inhibitor of survivin expression at both the mRNA and protein levels in vitro, significantly reducing survivin in bone metastatic C4-2 tumors |
|
| DCC1022 | Bkm1972 | Novel inhibitor of the expression of anti-apoptotic protein survivin and membrane-bound efflux pump ATP binding cassette B 1 (ABCB1, p-glycoprotein), presumably via signal transducer and activator of transcription 3 (Stat3), inhibiting human prostate canc |
|
| DCC1023 | Bkm-570 | Bradykinin antagonist, causing impressive growth inhibition of lung and prostate tumors, displaying superior in vivo inhibitory effects than convential chemotherapeutic drugs |
|
| DCC1024 | Blancoxanthone | Natural anti-coronavirus agent |
|
